News Corporate Actions Titan Biotech Limited Completes Equity Share Sub-Division Process with Depository ConfirmationTitan Biotech Limited Completes Equity Share Sub-Division Process with Depository Confirmation
Titan Biotech Limited has completed its equity share sub-division process, converting shares from Rs. 10 face value to Rs. 2 face value in a 1:5 ratio. Both NSDL and CDSL have confirmed the successful crediting of new shares under ISIN INE150C01029, with CDSL processing 28,621,985 new shares across 12,030 records and NSDL handling multiple tranches totaling over 12 million additional shares during February 21-27, 2026.
*this image is generated using AI for illustrative purposes only.
Titan Biotech Limited has successfully completed its equity share sub-division process, with both major depositories confirming the credit of new shares following the corporate action. The company notified BSE Limited on February 27, 2026, regarding the completion of the share split that was initially announced on December 31, 2025.
Share Sub-Division Details
The sub-division involved converting each equity share with a face value of Rs. 10 into 5 equity shares with a face value of Rs. 2 each, maintaining the fully paid-up status. The new shares have been credited under the revised ISIN: INE150C01029, replacing the original ISIN for the company's equity shares.
| Parameter: | Details |
|---|---|
| Original Face Value: | Rs. 10 per share |
| New Face Value: | Rs. 2 per share |
| Split Ratio: | 1:5 |
| New ISIN: | INE150C01029 |
| Execution Period: | February 21-27, 2026 |
Depository Confirmations
Both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) have provided confirmation letters detailing the successful execution of the corporate action. The depositories processed the sub-division through their respective systems with the assistance of the company's Registrar and Transfer Agent, Beetal Financial & Computer Services Pvt. Ltd.
CDSL Processing Summary
| Transaction Type: | Details |
|---|---|
| Credit Records: | 12,030 |
| New Shares Credited: | 28,621,985 |
| Debit Records: | 12,030 |
| Original Shares Debited: | 5,724,397 |
| Processing Date: | February 21, 2026 |
NSDL Processing Summary
NSDL processed the sub-division in multiple tranches, with confirmation letters dated February 23 and February 27, 2026. The transactions included:
| Date: | Transaction | Records | Quantity |
|---|---|---|---|
| February 21, 2026: | Debit (Original) | 4,602 | 2,331,302.000 |
| February 21, 2026: | Credit (New) | 4,602 | 11,656,510.000 |
| February 27, 2026: | Credit (Additional) | 1 | 1,040,005.000 |
Corporate Communication
The company's communication was signed by Charanjit Singh, Company Secretary & Compliance Officer, and submitted to BSE Limited under the company's scrip code 524717. The notification was made in compliance with Regulation 30 requirements, ensuring proper disclosure of the corporate action completion to the stock exchange and investors.
Titan Biotech Limited, an ISO 9001:2015 certified company, operates from multiple manufacturing units in Rajasthan and maintains its corporate office in Delhi. The successful completion of this share sub-division process demonstrates the company's commitment to enhancing share liquidity and making its equity more accessible to a broader investor base.
Historical Stock Returns for Titan Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.22% | -18.72% | -18.72% | -18.72% | -18.72% | -18.72% |
17
